Benign prostatic hyperplasia (BPH) is characterised by the development of lower urinary tract symptoms (LUTS), including voiding and storage problems, and has an increasing incidence in men over the age of 50 years. In the past, transurethral resection of the prostate (TURP) has been considered the standard of care surgical treatment. However, due to increasing adverse effects alternative therapy methods have been on the rise, including water vapour therapy and laser therapy. 

Water vapour therapy

Download further academic publications about water vapour therapy 

Laser therapy

Download further academic publications about laser therapy:


EAU, AUA and NICE guidelines

The European Association of Urology (EAU) and the American Urological Association (AUA) regularly publish a reference on effective, evidence-based surgical management of male lower urinary tract symptoms secondary to benign prostatic hyperplasia (LUTS/BPH). These references will provide you with a general recommendation on therapy methods that are considered recognised and safe.

GreenLightTM, AurigaTM XL and RezūmTM are included in the AUA guidelines.

GreenLight and Auriga XL have been fully recognized by the EAU and Rezūm is currently under investigation – an update will follow in due time.
(Last updated on July 1, 2019) 

In addition, the National Institute for Health and Care Excellence (NICE), a non-departmental public body that provides guidance and advice to improve health and social care in England, has provided guidance on vapour therapy, GreenLight and Auriga XL.


The BPH decision tree

Through a simple list of yes & no questions, the BPH decision tree has been developed to help during the decision-making process.17 

Stay up to date and subscribe to our newsletter :